Provided by Tiger Fintech (Singapore) Pte. Ltd.

Travere Therapeutics, Inc.

15.13
+0.22001.48%
Post-market: 15.130.00000.00%17:02 EDT
Volume:1.45M
Turnover:22.15M
Market Cap:1.34B
PE:-5.45
High:15.51
Open:15.04
Low:14.92
Close:14.91
Loading ...

Press Release: Travere Therapeutics Reports First Quarter 2025 Financial Results

Dow Jones
·
02 May

Travere, CSL Vifor Receive EU Marketing Approval for Filspari in IgA Nephropathy

MT Newswires Live
·
29 Apr

Travere Therapeutics and CSL Vifor Announce Standard EU Approval of Filspari® (Sparsentan) for Iga Nephropathy

THOMSON REUTERS
·
29 Apr

Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI® (sparsentan) for IgA Nephropathy

Business Wire
·
29 Apr

Travere, CSL Vifor announce EC approval of Filspari marketing authorization

TIPRANKS
·
29 Apr

BRIEF-CSL Vifor And Travere Therapeutics Announce Standard EU Approval For Filspari® In Iga Nephropathy

Reuters
·
29 Apr

CSL Vifor and Travere Therapeutics Announce Standard EU Approval for Filspari® in Iga Nephropathy

THOMSON REUTERS
·
29 Apr

Press Release: Travere Therapeutics to Report First Quarter 2025 Financial Results

Dow Jones
·
25 Apr

Exploring 3 High Growth Tech Stocks In The US Market

Simply Wall St.
·
24 Apr

Travere Therapeutics Price Target Maintained With a $47.00/Share by Guggenheim

Dow Jones
·
14 Apr

Travere Therapeutics Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
10 Apr

U.S. RESEARCH ROUNDUP- Carnival, JLL, Microsoft

Reuters
·
10 Apr

Travere Therapeutics Inc : Canaccord Genuity Raises Target Price to $47 From $45

THOMSON REUTERS
·
10 Apr

Novavax (NVAX) Soars 11.4%: Is Further Upside Left in the Stock?

Zacks
·
07 Apr

Travere Therapeutics (TVTX) Receives a Buy from Guggenheim

TIPRANKS
·
04 Apr

Travere Therapeutics Is Maintained at Buy by B of A Securities

Dow Jones
·
01 Apr

Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the National Kidney Foundation Spring Clinical Meetings 2025

Business Wire
·
01 Apr

BUZZ-U.S. STOCKS ON THE MOVE-Blackstone, PepsiCo, Blue Owl Capital

Reuters
·
18 Mar

BUZZ-Travere rises on co's marketing application for kidney disease drug

Reuters
·
17 Mar

Travere Therapeutics Shares up 4.8% After Co Submits US Marketing Application to the FDA for Kidney Disease Treatment

THOMSON REUTERS
·
17 Mar